NCCN 2017 Congress Series™: Lung Cancer
The American Cancer Society (ACS) has estimated that 224,390 new cases of lung cancer will be diagnosed in the United States in 2016 with an estimated 158,080 deaths expected. Lung cancer is the second most commonly diagnosed cancer and is the leading cause of cancer death. While a cure for cancer remains elusive, great progress has been made. The emergence of new biomarkers, advances in screening, and the availability of new systemic treatment options has changed the oncology landscape during the past five years. Clinicians need to be aware that the recommendations for sequencing systemic therapy for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are rapidly changing because of the availability of novel immunotherapeutic agents and targeted therapies. Health care providers and their patients need to be aware of the latest information about novel immunotherapeutic agents and targeted therapies including how to manage unusual adverse events that may occur with these agents. For lung cancer screening, new recommendations have been recently added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Lung Cancer Screening to improve the accuracy of screening. Plasma genotyping (also known as liquid biopsy) is a new tool that has expanded the options for assessing molecular markers for patients with NSCLC. Because of the rapidly evolving treatment and screening options, it is challenging for clinicians to remain up-to-date on new recommendations and guidelines. Recent updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for Non-Small Cell Lung Cancer, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for Small Cell Lung Cancer (SCLC) and NCCN Guidelines® for Lung Cancer Screening provide recommendations that can assist clinicians in managing their patients with lung cancer.
The goal of this congress is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with lung cancer and those being screened for lung cancer.
Hosted by: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with lung cancer and those being screened for lung cancer.
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 4.0 hours of Category I credit for completing this activity.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 4.0 contact hours.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 4.0 contact hours (0.4 CEUs) of continuing education credit. UAN: 0836-0000-17-078-L01-P
- 4.00 ACPE contact hours
- 4.00 ANCC contact hours
- 4.00 AMA PRA Category 1 Credit™
- 4.00 Participation
Following this activity, participants should be able to:
New Strategies to Improve the Accuracy of Lung Cancer Screening
- Discuss the risk assessment process used to determine whether patients are candidates for lung cancer screening.
- Evaluate and follow-up the findings of different types of nodules that may be detected on low-dose computed tomography.
- Identify when to recommend further screening, biopsy, surgical excision of nodules based on recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Lung Cancer Screening.
- Appropriately counsel patients about the risks and benefits of lung cancer screening.
What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer
- Identify the appropriate use of liquid biopsy and tissue biopsy in assessing for biomarkers in patients with metastatic non-small cell lung cancer (NSCLC).
- Describe the recommended molecular testing for patients with NSCLC and sensitizing EGFR mutations and T790M.
- Summarize the currently known mechanisms for primary and secondary resistance to erlotinib, gefitinib, and afatinib.
Immunotherapies in Lung Cancer
- Identify the new recommended immunotherapy regimens for patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- Evaluate the risks and benefits of using immune-checkpoint inhibitor therapy.
- Educate health care providers about adverse events that may occur with immunotherapy and appropriate management.
- Describe the challenges with diagnosing pneumonitis.
- Summarize the role of biomarker testing to assist with selecting the most appropriate immunotherapeutic agents for patients with metastatic NSCLC.
Sequencing Therapy for Advanced Non-Small Cell Lung Cancer
- Discuss sequencing of systemic therapy for patients with metastatic NSCLC and ALK gene rearrangements.
- Describe sequencing of systemic therapy for patients with metastatic NSCLC and sensitizing EGFR mutations.
- Identify the subsequent therapy regimens for patients with wild-type NSCLC.
- Select the most appropriate subsequent therapy regimens for patients with advanced NSCLC who have progressed after first-line systemic therapy.
- Discuss sequencing of systemic therapy for patients with metastatic NSCLC and ROS1 gene rearrangements.
- Describe the different biomarkers for which effective targeted therapy is available for patients with metastatic NSCLC.
Managing Toxicities of Newer Agents
- Describe the spectrum of immune-related adverse events that may occur with immune-checkpoint inhibitor therapy.
- Educate patients and their caregivers about symptoms suggestive of immune-related adverse events.
- Manage immune-related adverse events associated with immune-checkpoint inhibitor therapy.
- Monitor for and manage patients who have adverse events associated with ALK inhibitors.
There is a registration fee of $149.00 for industry and a registration fee of $49.00 for health care providers.